Skip to content

Annexon ANNX Net Income

Net Income at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$727.2M-10.1%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$40.83M-38.4%
Omeros logo
OmerosOMER
$56.06M+268%
Vor Biopharma logo
Vor BiopharmaVOR
-$219.59M-576%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$49.66M-2.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$44.9M+11.7%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's net income?
Annexon (ANNX) reported net income of -$44.14M in Q1 2026.
How has Annexon's net income changed year-over-year?
Annexon's net income increased by 18.8% year-over-year, from -$54.36M to -$44.14M.
What is the long-term trend for Annexon's net income?
Over 4 years (2021 to 2025), Annexon's net income has grown at a 12.2% compound annual growth rate (CAGR), from -$130.32M to -$206.69M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.